The chronic obstructive pulmonary disease (COPD) market is becoming increasingly crowded, but significant unmet need remains due to the lack of a disease-modifying therapy. In recent years, several new combination therapies have been approved for the treatment of COPD, further increasing the competition. Although these new therapies perform well on a variety of clinical end points, most offer only incremental improvements, and none have yet demonstrated a statistically significant decrease in all-cause mortality. Owing to the high level of unmet need in COPD, significant clinical and commercial opportunity remains for therapies that can provide a decrease in all-cause mortality, number of exacerbations, or improvement on several clinically important end points, including FEV1 and frequency of exacerbations, compared with current standards of care.

Table of contents

  • Chronic Obstructive Pulmonary Disease - Unmet Need - Detailed, Expanded Analysis
    • Treatment Drivers and Goals
      • Overview
      • Physician Rating of Treatment Drivers and Goals in Chronic Obstructive Pulmonary Disease
        • Importance of Efficacy Attributes to Prescribing Decisions in Chronic Obstructive Pulmonary Disease — United States
        • Importance of Efficacy Attributes to Prescribing Decisions in Chronic Obstructive Pulmonary Disease — Europe
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Chronic Obstructive Pulmonary Disease — United States
        • Importance of Convenience of Administration Attributes to Prescribing Decisions in Chronic Obstructive Pulmonary Disease — Europe
        • Importance of Non-Clinical Factors to Prescribing Decisions in Chronic Obstructive Pulmonary Disease — United States
        • Importance of Non-Clinical Factors to Prescribing Decisions in Chronic Obstructive Pulmonary Disease — Europe
      • Stated Versus Derived Importance of Treatment Drivers and Goals
        • Stated Versus Derived Importance of Key Efficacy, Convenience of Administration, and Non-Clinical Attributes to Prescribing Decisions in Chronic Obstructive Pulmonary Disease — United States
        • Stated Versus Derived Importance of Key Efficacy,Convenience of Administration, and Non-Clinical Attributes to Prescribing Decisions in Chronic Obstructive Pulmonary Disease — Europe
    • Product Performance Against Treatment Drivers and Goals
      • Overview
      • Rationale for Drug Selection
        • Products for Chronic Obstructive Pulmonary Disease
      • Current Brand Performance on Key Treatment Drivers and Goals
        • Overall Performance of Key Therapies for Chronic Obstructive Pulmonary Disease — United States
        • Overall Performance of Key Therapies for Chronic Obstructive Pulmonary Disease — Europe
        • Relative Performance of Key Therapies for Chronic Obstructive Pulmonary Disease Across Select Efficacy Attributes — United States
        • Relative Performance of Key Therapies for Chronic Obstructive Pulmonary Disease Across Select Efficacy Attributes — Europe
        • Relative Performance of Key Therapies for Chronic Obstructive Pulmonary Disease Across Select Convenience of Administration Attributes — United States
        • Relative Performance of Key Therapies for Chronic Obstructive Pulmonary Disease Across Select Convenience of Administration Attributes — Europe
        • Relative Performance of Key Therapies for Chronic Obstructive Pulmonary Disease Across Select Non-Clinical Attributes — United States
        • Relative Performance of Key Therapies for Chronic Obstructive Pulmonary Disease Across Select Non-Clinical Attributes — Europe
    • Assessment of Unmet Need
      • Overview
      • Overall Satisfaction with Current Treatment
        • Surveyed Pulmonologists' Satisfaction with the Performance of Key Therapies for Chronic Obstructive Pulmonary Disease on Efficacy, Convenience of Administration, and Non-Clinical Factors — United States
        • Surveyed Pulmonologists' Satisfaction with the Performance of Key Therapies for Chronic Obstructive Pulmonary Disease on Efficacy, Convenience of Administration, and Non-Clinical Factors — United States — Europe
      • Physician Rating of Unmet Need in Chronic Obstructive Pulmonary Disease
        • Surveyed Pulmonologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Chronic Obstructive Pulmonary Disease — United States
        • Surveyed Pulmonologists' Ascribed Level of Unmet Need Across Key Efficacy Attributes in Chronic Obstructive Pulmonary Disease — Europe
        • Surveyed Pulmonologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Chronic Obstructive Pulmonary Disease — United States
        • Surveyed Pulmonologists' Ascribed Level of Unmet Need Across Key Convenience of Administration Attributes in Chronic Obstructive Pulmonary Disease — Europe
        • Surveyed Pulmonologists' Ascribed Level of Unmet Need Across Key Non-Clinical Factors in Chronic Obstructive Pulmonary Disease — United States
        • Surveyed Pulmonologists' Ascribed Level of Unmet Need Across Key Non-Clinical Factors in Chronic Obstructive Pulmonary Disease — Europe
      • Unmet Need in Chronic Obstructive Pulmonary Disease and Related Indications
        • Surveyed Pulmonologists' Ascribed Level of Unmet Need in Chronic Obstructive Pulmonary Disease and Related Indications — United States
        • Surveyed Pulmonologists' Ascribed Level of Unmet Need in Chronic Obstructive Pulmonary Disease and Related Indications — Europe
    • Opportunity Analysis
      • Areas of Opportunity in the Chronic Obstructive Pulmonary DiseasMarket and Emerging Therapy Insights
        • Opportunity: A Combination Therapy That Improves Overall Survival
        • Opportunity: A Biologic or Small-Molecule Therapy That Reduces Inflammation and Exacerbations
        • Opportunity: Therapies That Outperform Current Drugs on FEV1 and TDI Focal Score
        • Opportunity: Therapies That Are More Convenient and Have a Decreased Dosing Burden
    • Target Product Profiles
      • Assessing Drug Development Opportunities
      • Target Product Profile Methodology
        • Attributes and Attribute Levels
      • Attribute Importance and Part-Worth Utilities
        • Chronic Obstructive Pulmonary Disease Target Product Profile: Attribute Importance
        • Chronic Obstructive Pulmonary Disease Target Product Profile: Attribute-Level Part-Worth Utilities
      • Conjoint Analysis-Based Simulations of Market Scenarios
        • Chronic Obstructive Pulmonary Disease Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 1
        • Chronic Obstructive Pulmonary Disease Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 1
        • Chronic Obstructive Pulmonary Disease Market Simulations: Target Product Profiles Included in Scenario 1
        • Chronic Obstructive Pulmonary Disease Market Simulations: Share of Preference of Target Product Profiles Included in Scenario 2
        • Chronic Obstructive Pulmonary Disease Market Simulations: Likelihood to Prescribe Target Product Profiles Included in Scenario 2
        • Chronic Obstructive Pulmonary Disease Market Simulations: Target Product Profiles Included in Scenario 2

Author(s): Kristine Mackin, PhD

Kristine Mackin, Ph.D., is an analyst on the immune and inflammatory disorders team at Decision Resources Group. She currently focuses on respiratory diseases, including asthma and COPD.

She holds a doctorate in biochemistry from Brandeis University, where she studied the evolution of bacteriorhodopsin and the relationship between type I and type II rhodopsins. During her B.A. in Chemistry at Carleton College, she researched proinsulin processing. Prior to joining DRG, Dr. Mackin was involved with literature and market research for a new company pitch during an internship at Puretech Ventures in Boston, MA.


Related Reports

Chronic Obstructive Pulmonary Disease - Landscape & Forecast - Disease Landscape & Forecast

The large therapeutic market for chronic obstructive pulmonary disease (COPD), a disease that is closely associated with smoking, continues to expand and is expected to grow from approximately $15...

View Details

Chronic Obstructive Pulmonary Disease | Disease Landscape and Forecast | G7 | 2020

The chronic obstructive pulmonary disease (COPD) therapy market is continuing its gradual shift away from long-acting beta2 agonist/inhaled corticosteroid fixed-dose combinations (LABA/ICSFDCs) tow...

View Details

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Janssen Proprietary Content

In this project, comissioned by Janssen in December, 2018, we have packaged our published estimates on the epidemiology of CLL - drug treated population across all the countries in Latin Ameri...

View Details